MedPath

Phase II study of neoadjuvant chemoradiotherapy of s-1 and cisplatin for advanced gastric cancer with lymph node metastases (Neo-KOGC04 study)

Not Applicable
Conditions
Advanced Gastric Cancer
Registration Number
JPRN-UMIN000014331
Lead Sponsor
School of Medicine, Keio University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1) contraindication of either S-1 or cisplatin 2) with severe infection 3) with interstitial pneumonia or pulmonary fibrosis 4) with severe diarrhea 5) with severe complication (intestinal paralysis, ileus, diabetes, renal dysfunction, liver dysfunction) 6) with other active malignant disease 7) pregnant or nursing women or women who like be pregnant and willing to get pregnant

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate of neoadjuvant chemoradiotherapy
Secondary Outcome Measures
NameTimeMethod
Pathological response rate, compliance of neoadjuvant therapy, compliance of adjuvant therapy, curable resection rate, rate of adverse event, 3-year Relapse-free survival, 3-year Overall survival
© Copyright 2025. All Rights Reserved by MedPath